Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells

Om V. Singh, Neeraj Vij, Peter J. Mogayzel, Cathy Jozwik, Harvey B. Pollard, Pamela L. Zeitlin

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


4-Phenylbutyrate (4-PBA) is an oral butyrate derivative that has recently been approved for treatment of urea cycle disorders and is under investigation in clinical trials of cancer, hemoglobinopathies, and cystic fibrosis (CF). We hypothesized that proteome profiling of IB3-1 cystic fibrosis bronchial epithelial cells treated with 4-PBA would identify butyrate-responsive cellular chaperones, protein processing enzymes, and cell trafficking molecules associated with the amelioration of the chloride transport defect in these cells. Protein profiles were analyzed by two-dimensional gel electrophoresis and mass spectrometry. Over a p/range of 4-7 and molecular weight from 20 to 150 kDa a total of 85 differentially expressed proteins were detected. Most of the identified proteins were chaperones, catalytic enzymes, and proteins comprising structural elements, cellular defense, protein biosynthesis, trafficking activity, and ion transport. Subsets of these proteins were confirmed by immunoblot analysis. These data represent a first-draft of the pharmacoproteomics map of 4-PBA treated cystic fibrosis bronchial epithelial cells.

Original languageEnglish (US)
Pages (from-to)562-571
Number of pages10
JournalJournal of proteome research
Issue number3
StatePublished - Mar 2006


  • Chaperone
  • Chloride transport
  • Cystic fibrosis
  • Proteasome
  • Two-dimensional gel electrophoresis

ASJC Scopus subject areas

  • Biochemistry
  • General Chemistry


Dive into the research topics of 'Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells'. Together they form a unique fingerprint.

Cite this